UC2288
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| HY-112780-5MG | 5 mg | 165,00 | Add | |
| HY-112780-1ML | 10mM/1mL | 181,00 | Add | |
| HY-112780-10MG | 10 mg | 241,00 | Add | |
| HY-112780-25MG | 25 mg | 438,00 | Add | |
| HY-112780-50MG | 50 mg | 647,00 | Add | |
| HY-112780-100MG | 100 mg | 799,00 | Add | |
| HY-112780-250MG | 250 mg | 1'027,00 | Add | |
| HY-112780-S-1ST | Sample | Inquire |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
UC2288 is a novel, cell-permeable, and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 decreases p21 mRNA expression independently of p53, and attenuates p21 protein levels with minimal effect on p21 protein stability. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1].
| Category | Protein |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer, Apoptosis |
| Format | Solubility: DMSO : 50 mg/mL (ultrasonic);Ethanol : 12.5 mg/mL (ultrasonic) |
| Grade | Clinical information: No Development Reported |
| Purity | 99.92% |
| Molecular Formula | C20H18ClF6N3O2 |
| Molecular Weight | 481.82 |
| CAS-Number | 1394011-91-6 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
